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Historical and current concepts of in vitro fibrillogenesis are considered in the light
of disorders in which amyloid is deposited at anatomic sites remote from the site
of synthesis of the corresponding precursor protein. These clinical conditions set
constraints on the interpretation of information derived from in vitro fibrillogenesis studies.
They suggest that in addition to kinetic and thermodynamic factors identified in vitro,
fibrillogenesis in vivo is determined by site specific factors most of which have yet to be
identified.
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INTRODUCTION
Until relatively recently “amyloid” was considered to be a relatively rare and esoteric medical
entity. A “Pubmed” search of the term “amyloid” by decade indicates but two publications for the
period 1921–1930 and eight for 1931–1940. This increase in number accelerated over the next four
decades and reached ∼25,000 for the period 2001–2010. Given the number of publications for
2011–2015 the projected result for 2011–2020 is of the order of 50,000 (Figure 1). Furthermore,
amyloid involvement in common disorders such as Alzheimer’s disease and type 2 diabetes as well
as forms (e.g., prions) that may be transmitted through our food supply have made it a subject of
interest to diverse clinicians and basic scientists (Figure 2). Most importantly existing therapeutic
modalities that prevent continuous amyloid deposition allows the mobilization of existing deposits
with clinical improvement. Such observations indicate that amyloid does turn over and its presence
in tissue has adverse effects on physiological function. Amyloid is not simply a “tombstone” of
previous injuries.
The history of “amyloid” as it relates to its composition, structure, and the pathogenetic
mechanism of tissue deposition has been the subject of several extensive recent reviews (Sipe
and Cohen, 2000; Kyle, 2001; Westermark, 2005). We will focus primarily on more modern
concepts that may promote, or potentially confound, future progress. This is particularly true
of in vivo amyloidogenesis that occurs at tissue sites remote from the biosynthetic origin of
Abbreviations: AA, amyloid A; Aβ, amyloid-beta; Aβ2M, beta-2-microglobulin amyloid; AEF, amyloid enhancing factor;
AIAPP, islet amyloid polypeptide amyloid; AL, immunoglobulin light-chain amyloid; apoAI, apolipoprotein AI; apoE,
apolipoprotein E; ATTR, transthyretin amyloid; β2M, beta-2-microglobulin; GAG, glycosaminoglycan; HDL, high density
lipoprotein; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan; IAPP, islet amyloid polypeptide; NMR, nuclear
magnetic resonance; SAA, serum amyloid A; SAP, serum amyloid P; TTR, transthyretin.
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the corresponding amyloid precursor protein. For example, in
animal models that mimic the form of human amyloid seen
after persistent acute inflammation, amyloid is derived from
the acute-phase protein serum amyloid A (SAA). This protein
is synthesized primarily in the liver but is first deposited
in very specific anatomic sites such as the follicular and
perifollicular zones of the spleen, which are remote from its site
of synthesis (Snow and Kisilevsky, 1985). More remarkably a
different amyloidogenic protein, transthyretin (TTR), apparently
has different tissue affinities after the substitution of but
single amino acids, products of genetic mutations (Benson,
1996; Benson and Uemichi, 1996; Saraiva, 2001). A similar
observation has been made recently in the case of beta-2-
microglobulin (β2M; Valleix et al., 2012; Mangione et al.,
2013). Why and how does amyloid in vivo get to be
deposited at particular cell or tissue sites and does this tell
us anything about current concepts that are based on in vitro
studies?
FIGURE 1 | “Amyloid” publications by decade determined from
pubmed.
FIGURE 2 | The broad diversity of interests in amyloid.
PATHOGENESIS OF AMYLOID
DEPOSITION IN VIVO
During the 1890s it was noticed that immunization of horses
for the production of diphtheria antisera led to systemic
amyloidosis. Rabbits and mice immunized with foreign antigens
also developed systemic amyloid deposition. These observations
raised the possibility that a disturbance of the immune system
played a role in amyloidogenesis. This concept was consistent
with clinical and histological observations though no clearly
defined mechanism was invoked. In the early 1970s, when
this vague immunological idea was still prevalent, experiments
were performed to determine whether “immunological memory”
(in the sense that the immune system “remembers” previous
exposure to defined antigens and reacts much more rapidly
on second exposure to the antigen than following the first)
played a role in amyloidogenesis (Axelrad et al., 1975, 1982;
Axelrad and Kisilevsky, 1980). The results of these investigations
inadvertently led to the recognition of a biological property called
“amyloid enhancing factor” (AEF) which, on the basis of kinetic
data, appeared to function in vivo as a “seed” for fibrillization
(Kisilevsky and Boudreau, 1983). Furthermore, in the presence
of AEF any acute inflammatory stimulus, immunogenic or not,
could very rapidly trigger amyloid deposition of the AA type
(Axelrad et al., 1975, 1982; Axelrad and Kisilevsky, 1980). This
observation, among others to be considered below, began to




It is generally accepted that the first description of organ
involvement by what we now consider to be amyloid was made
by Nicolaus Fontanus in 1639. Little additional understanding
occurred for another 150–200 years. The possibility that lipid-
like material was the basic nature of amyloid was implied by
the descriptive term “lardaceous” used by Portal, Merat, and
Frontiers in Molecular Biosciences | www.frontiersin.org 2 May 2016 | Volume 3 | Article 17
Kisilevsky et al. Amyloidogenesis and Amyloid Tissue Targeting
Rokitansky in reports of the period 1789–1842 (cf Kyle, 2001).
“Amyloid” meaning starch-like (from the Greek “amylon” for
starch) was coined by Schleiden in 1838 (cf Kyle, 2001) for
botanical purposes and was applied (Virchow, 1854) to organ
amyloid based on its positive reaction with iodine in an acidic
environment, the chemical reaction being used to identify starch
or cellulose. Virchow’s interpretation of the positive result was
that amyloid was starch-like in nature, which implied that it
was a carbohydrate. His conclusion was not completely accurate.
Nonetheless, the name persists as does the concept that a
carbohydrate is part of amyloid deposits in vivo (discussed
below).
Initial histological observations (1859–1920) based on dye
interactions with tissue sections suggested that the amyloid
deposits were “albuminoid” in nature (Friedrich and Kekule,
1859), namely protein, and possessed no particular organization
(cf Kyle, 2001). The development of Congo red in 1883
for use in the textile industry and subsequent use for the
staining of tissue sections for microscopy was instrumental
in changing this view (Bennhold, 1922). The red/green
birefringence observed in Congo red stained tissue sections
when viewed in polarized light indicated a very well ordered
repetitive super-structure which conferred the characteristic
optical properties to amyloid upon its binding of Congo red
(Howie et al., 2008; Howie and Brewer, 2009). However,
the nature of this structure remained elusive until the
1950s.
The advent of the electron microscope and its application
to amyloid tissue deposits (1950s) revealed the fibrillar nature
of amyloid (Cohen and Calkins, 1959), changed our concept
of its structure and provided a specific direction for amyloid
research to follow. The challenge was to isolate these fibrils
and then determine the protein responsible for its structure
(singular, since at that time amyloid was thought to be the
same regardless of its tissue of origin). In the late 1960s
groups in Israel (Pras et al., 1968; Franklin and Pras, 1969),
and Boston (Cohen and Calkins, 1964), developed techniques
to liberate fibrils from tissues containing amyloid and it was
assumed that the structure of such liberated fibrils (ex vivo
fibrils) was identical to those found in situ. This may or may
not be true and will be addressed in greater detail below
as it bears on several additional concepts and conclusions
that are driving current research. Regardless, this technical
achievement led to an explosion of information concerning
the structure of ex vivo and in vitro fibrils, their composition,
identification of the various amyloidogenic peptides and
their protein precursors, and characterization of structural
modifications and intermediates that occur during the in vitro
conversion of the globular precursor into fibrils. It provided the
impetus to:
1. determine where and under what conditions biosynthesis of
each of the amyloidogenic proteins took place,
2. conduct genetic analyses and distribution of specific forms of
amyloidosis in human populations,
3. identify particular mutations that enhance the amyloidogenic
potential of the protein concerned, and,
4. develop techniques for the in vitro study of fibrillogenesis to
elucidate the kinetics and thermodynamics of protein fibril
assembly and the fine structure of such fibrils.
In 1970 the first amyloid protein was isolated from natural
deposits occurring in a patient affected by multiple myeloma and
amyloidosis. This amyloid protein was composed mainly of a
fragment of a monoclonal light chain whose primary structure
was identical to the variable region of the monoclonal light
chains isolated from the patient’s urine (Glenner et al., 1970,
1971a,c). At that time amyloid was still thought to be the
same regardless of its clinical setting or tissue of origin, and
the observation that an immunoglobulin could form amyloid
was consistent with the then prevailing view that amyloid was
a product of a derangement in immune function. Additional
evidence supporting this idea came from the clinical settings in
which amyloid was frequently seen such as persistent infections
(e.g., tuberculosis, osteomyelitis), auto-immune diseases (e.g.,
rheumatoid arthritis or ankylosing spondylitis) and malignancies
of the immune system (e.g., multiple myeloma and B-cell
dyscrasias). Moreover, the cell types seen in the tissues affected in
such diseases were lymphocytes, macrophages, and plasma cells,
cells of the immune system. Not surprisingly between the 1890s
and 1970 the primary concept concerning the pathogenesis of
amyloid was a poorly defined disturbance of immune function
in which proteolytic fragmentation of the immunoglobulin light-
chain led to the deposition of these fragments as amyloid. This
conclusion was supported by in vitro studies with Bence-Jones
protein (themonoclonal light chain present in urine) which when
treated with trypsin generated fibrils that appeared identical to
those extracted from tissue (Glenner et al., 1971a; Glenner, 1972).
Analysis of these ex vivo fibrils, and those created in vitro, by X-
ray diffraction and subsequently infra-red spectroscopy revealed
an underlying crossed beta-sheet organization (Glenner et al.,
1971b; Harada et al., 1971).
Thus, by the early 1970s, the accumulated data laid
the foundation for most of the concepts driving current
investigations. A more detailed definition of amyloid was
framed: when examined in situ amyloid appeared amorphous
with routine stains and light microscopy; amyloid stained with
Congo red when viewed in polarized light exhibited red/green
birefringence; ultrastructurally amyloid was composed of fibrils;
and fibrils extracted from tissue as well as fibrils generated in
vitro possessed a characteristic X-ray diffraction pattern. Though
pathologists in the 1930’s observed subtle staining differences
with Congo red between primary (now AL) and secondary
(now AA) amyloid which suggested an underlying difference in
chemical composition, in the late 1960s to early 1970s, amyloid
was still considered to be a product of a single protein, likely an
immunoglobulin light-chain, and proteolysis was believed to be a
critical step in its conversion to fibrils. Furthermore, the fibrils
seen ex vivo and those generated in vitro were thought to be
identical to those seen in situ.
Substantial progress has been made regarding protein fibril
structure since the early 1970’s. A large literature is now available
which describes the kinetics and thermodynamics of amyloid-like
fibril assembly in vitro, and under appropriate in vitro conditions
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virtually any protein has the potential to change conformation
and acquire substantial beta-sheet structure (cf Buell et al.,
2014). In the last 4–5 years the application of protein magic
angle spin solid state NMR to the structural characterization
of ex vivo amyloid fibrils from different proteins is providing
fundamental atomic details on the structure of amyloidogenic
monomers and the type of intermolecular interactions that exist
between these monomers (Petkova et al., 2006; Wasmer et al.,
2008; Barbet-Massin et al., 2010; Debelouchina et al., 2010,
2013; Comellas et al., 2011; Hellmus et al., 2011). Through
solid state NMR in combination with high resolution cryo-
electron microscopy and atomic force microscopy the general
3D structure of ex vivo amyloid fibrils is emerging as well as the
specific structural differences contributed by the different types
of amyloidogenic proteins. Recent work (Lu et al., 2013) on the
structure of Aβ amyloid fibrils seeded on Aβ amyloid plaques
in brain homogenates attempted to exploit the potency of this
technology in revealing subtle but important differences between
fibrils obtained in vitro and fibrils grown on a substrate of
natural Aβ amyloid plaques, or possibly the extracellular matrix
(stroma) components within such plaques (Snow et al., 1988,
1989; Narindrasorasak et al., 1991). Though differences in Aβ
fibril structure were observed in the presence and absence of
Aβ plaques in the homogenates the results also proved different
from in vitro Aβ fibril assemblies as seen with cryo-electron
microscopy (Fandrich et al., 2011). It is still not clear which
of these results reflect the in situ situation. The presence of
unexpected twists in particular strands, or novel orientation of
side chains of specific amino acid residues, as a result of the
influence of the plaque or its stroma, may be very relevant in
dictating the physical properties of fibrils in situ. They may
also influence the kinetics of fibrils growth and generate specific
conformations suitable for the binding of various ligands. These
data raise the distinct possibility that in vivo components of tissue
stroma have a role in the structure and potentially the anatomic
site of the deposition process itself. This idea is consistent with
the known presence of such components, e.g., serum amyloid
P (SAP), apolipoprotein E (apoE), glycosaminoglycans (GAGs)
such as heparan sulfate (HS), HS proteoglycan (HSPG), laminin
and particular forms of collagen, in amyloid fibrils in situ (Lyon
et al., 1991). Experimental studies examining fibrillogenesis of
different amyloidogenic proteins on different tissue, or synthetic,
matrices will probably become a ripe area for investigation and
may succeed in enlightening us about the possible differences
and similarities between amyloid-like fibrils in vitro and in situ
amyloid fibrils. Initial explorations in this direction have already
begun (Mazza et al., 2016).
Notwithstanding the substantial advances made
understanding protein fibrillogenesis and fibril structure in
vitro, progress regarding these processes in situ/in vivo has
not proceeded apace. Currently, structural comparisons of ex
vivo/in vitro fibrils with those observed in situ rest on relatively
few studies. One similarity is their common Congo red and
thioflavin T staining properties. There are but two infra-red
studies of in situ amyloid, one examining procalcitonin and
the other Aβ amyloids in situ (O’Leary and Levin, 1985; Choo
et al., 1996). There is but a single X-ray microprobe study of
Aβ in situ (Briki et al., 2011), a single cryo-fixation, freeze
substitution and standard EM study of AA amyloid fibrils in situ
(Inoue and Kisilevsky, 1999; Inoue et al., 2002), and one study of
transthyretin amyloid fibrils extracted from the vitreous of the
eye from a patient with a familial form of ATTR (Serpell et al.,
1995). Whether the large body of information on in vitro/ex vivo
fibrils and the limited structural information on in situ fibrils
is sufficient to establish equivalence between the two sources of
fibrils has yet to be settled.
The understanding of fibril composition and structure
achieved from 1970 onwards rendered incorrect some pre-
existing concepts concerning the make-up of amyloid and its
pathogenesis and required significant amendments. In 1970–
1972 data emerged from several groups that at least one
amyloid protein was not related to immunoglobulins (Benditt
et al., 1971; Benditt and Eriksen, 1971, 1972; Ein et al., 1972;
Hermodson et al., 1972). In 1970–1980, in addition to the AEF
studies which questioned the role of immune mechanisms in
AA amyloidogenesis, it became apparent that several different
proteins could be responsible for amyloid deposits in vivo.
During this period at least a dozen such proteins were identified
and the number has now climbed to over 30 (Westermark
et al., 2007). Each amyloid protein was shown to be associated
with a distinct clinical disorder or pathologic process. The
older idea that amyloid was always due to the same protein,
regardless of tissue source, or clinical disorder, had to be
discarded. Furthermore, many of the identified proteins had
little, if anything, to do with immune function and the concept
that an undefined immunological disturbance was at the basis
of all amyloids has also been discarded. Moreover, not all of the
identified amyloidogenic proteins appeared to require proteolysis
for fibril assembly. There are multiple examples in which the
full length unmodified protein is present in the natural fibrils
which include SAA in ducks (Ericsson et al., 1987), a mutant
variant of lysozyme (Pepys et al., 1993), and the natural variant
of β2M (Valleix et al., 2012). Nor was it clear whether in
some cases proteolytic cleavage was a pre- or post-fibrillogenic
in vivo event. Since many of the tissue amyloid deposits had
existed in vivo for months or years prior to their isolation
and examination it remained possible that in vivo proteolytic
attack occurring after deposition could generate a family of
related peptides that could be purified from the isolated fibrils
(Kisilevsky et al., 1994; Röcken et al., 2000; Enqvist et al.,
2009). It is also possible that truncated species of a protein
precursor, chemically identical to those found in natural fibrils,
possesses strong amyloidogenic propensity (Esposito et al., 2000;
Mangione et al., 2014), and can generate a fibril nucleus able
to catalyze the aggregation of the less amyloidogenic full length
protein.
Despite the wealth of basic knowledge on the biophysical
basis of fibrillogenesis of native proteins in vitro the reasons
why relatively few of the 20,000–25,000 proteins encoded by
the genome are associated with amyloid deposition in humans
and the mechanisms that drive the tissue selectivity of systemic
amyloid deposition remains totally unexplained. Nevertheless,
the acquired data have raised many questions related to
amyloidogenesis, among which are:
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1. Is the cross beta-sheet structure of a fibrillar protein aggregate
the lowest free energy state of that polypeptide, and is the
main driving force for the conformational transition of the
amyloidogenic protein in vivo the energy landscape in which
it exists?
2. Are the in vitro fibrillogenic conditions ones that might be
seen in vivo, and if so where do these occur anatomically?
3. Are the amyloid-like fibrils generated in vitro from a single
protein really identical to, or only similar to, amyloid fibrils
seen in vivo?
4. What role do co-precipitating components (e.g., SAP,
GAGs, laminin, and type IV collagen of the extracellular
matrix) known to be part of in vivo amyloid deposits
play in amyloidogenesis (Kisilevsky, 2000)? Are they simply
“associated” factors, or “critical” components, as suggested
by inhibition of in vivo fibrillogenesis when one alters the
availability of SAP (Pepys et al., 2002; Inoue et al., 2005; Bodin
et al., 2010), or the state and/or quantity of HS (Kisilevsky
et al., 2007).
5. Has our current focus primarily on proteins identified in
amyloid-like fibrils inadvertently altered our definition of
amyloid so that it has lost its previous clinical and pathological
context? Has amyloid’s original definition therefore become
distorted to a “protein only” entity and problem? Such a
perspective would distract/deflect us from understanding the
role of additional components in amyloid structure, the
more complex details of fibrillogenesis in vivo involving
these additional components and potentially prevent us from
considering broader therapeutic possibilities derived from an
understanding of these complexities.
6. What roles do natural inhibitors of protein mis-folding, and
stabilizers of protein conformation, (the “chaperones”) play in
amyloidogenesis in vivo?
7. How does a critical concentration of an amyloidogenic protein
arise at anatomic sites remote from its site of biosynthesis?
8. How do amyloid deposits influence cell and tissue function
and viability?
The basic concepts concerning protein folding and misfolding
and their possible relationship to protein fibril assembly and
amyloid formation are schematically presented in Figure 3,
which is reproduced from Hartl and Hayer-Hartl (2009). In
this scheme fibril formation is driven thermodynamically by
the very low free energy of the fibrillar state. This deep free
energy minimum is derived from the extensive formation of
intermolecular hydrogen bonds, hydrophobic interactions and
water exclusion from the inner core of the fibril. In the
case of systemic amyloidoses the pathway of amyloidogenesis
begins with native globular proteins that circulate freely in
plasma, diffuse into the interstitial space but ordinarily possess
a “local” free energy minimum that, in effect, prevents them
from cascading further down the free energy scale unless they
are perturbed to overcome this energy barrier. In vitro this
barrier can be “softened” by altering the conditions in which
the globular protein exits, such as increasing the temperature,
reducing the pH, introducing organic solvents, changing the
sequence of the normal protein, or removing an associated
FIGURE 3 | Energy landscape scheme of protein folding and
aggregation. Reproduced, with permission, from Hartl and Hayer-Hartl
(2009).
protein (Hatters et al., 2001; Rekas et al., 2004; Raman et al., 2005;
Mangione et al., 2013). The sources providing sufficient energy
to overcome the barrier in vivo are still largely undetermined and
some proteins intrinsically amyloidogenic in in vitro experiments
never overcome the barrier in vivo. Wild-type lysozyme is
an example of a potentially amyloidogenic protein that never
appears to enter the amyloid pathway. However, mutations
may alter the minimum free energy of the native, and or, the
intermediate states, effectively altering the free energy landscape
making it possible (step 1, Figure 3) to proceed to a partially
unfolded intermediate state. This intermediate and metastable
state (step 2, Figure 3) appears to be a key step in any further
transformation and a crucial entity in amyloid conversion. The
intermediate state is most likely a population of heterogeneous
conformers whose structural characterization is extremely
difficult due to their rapid inter-conversions. The formation of
an intermediate state in vivo has not yet been demonstrated but
all in vitro evidence would indicate this also occurs in living
systems.
A necessary property of any amyloidogenic globular protein
appears to be its folding instability and almost all the methods of
in vitro fibrillogenesis are based on conditions inducing a partial
protein unfolding (Bellotti and Chiti, 2008). Several groups have
investigated the fibrillogenesis of β2M which provides a good
example of the evolution of concepts and methods related to the
formation of amyloid-like fibrils in vitro (Stoppini and Bellotti,
2015). This progressed through the use of full length β2M and
fibrillogenic seeding at low pH, alterations in salt composition
and concentration, use of truncated, or partially unfolded, forms
of β2M, introduction of GAGs at more neutral pH, use of
phosphate buffers and the use of a natural amyloidogenic variant
(Naiki et al., 1997; Esposito et al., 2000; McParland et al., 2000;
Chiti et al., 2001; Yamamoto et al., 2004a,b; Jahn et al., 2006;
Relini et al., 2008; Eichner and Radford, 2011; Mangione et al.,
2013).
Recent additional work on the first natural amyloidogenic
variant of β2M has highlighted the role of shear forces generated
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by the flow of physiologic fluids and the exposure of this variant
to hydrophobic surfaces (Valleix et al., 2012; Mangione et al.,
2013). In particular in this variant the replacement of Asp76 by
Asn destabilizes the folded state by 2.8 kcal/mol. Nevertheless, in
the cell, this variant is fully folded and functions properly through
its stabilizing interaction with the Class I major histocompatibilty
complex (Halabelian et al., 2014). A further property of this
mutant form of β2M is that the single amino acid substitution
drives the anatomic site of amyloid deposition. In fact the wild-
type β2M is found primarily in large joints, bones and ligaments
but the mutant form is deposited systemically.
AMYLOID CELL AND TISSUE TARGETING
IN VIVO
In vivo deposition of amyloid may occur at, or close to, the
biosynthetic site of its amyloidogenic precursor, or at a site
remote from its site of synthesis. When at or near the site
of biosynthesis, fibrillogenesis may occur within the cell or
close to it extracellularly. Examples of the former are fibrils
found within light-chain synthesizing plasma cells in multiple
myeloma (Ishihara et al., 1991), phosphorylated tau fibrils found
in neurons containing neurofibrillary tangles (Ruben et al., 1992;
Snow et al., 1992), islet amyloid polypeptide (IAPP) in β-cells of
the islets of Langerhans (de Koning et al., 1994b; Westermark
et al., 2011) and amyloid-like fibrils seen in various species of
yeast (Wickner et al., 2013). In each of these situations one
can imagine an intracellular synthesized protein experiencing
conditions (mutations, temperature, pH, shear forces, protein
concentration, or lack of proper chaperones) that alter the
stability of the folded protein creating a micro-environment
conducive to the generation of conformational intermediates,
oligomer formation, and finally fibril formation as one sees in
vitro.
In addition to being a protein that undergoes intracellular
fibrillogenesis IAPP is also an example of extracellular amyloid
deposited close to its site of synthesis. It is believed that Aβ
deposits in the central nervous system in Alzheimer’s disease may
represent another such example. These proteins are synthesized
by local cells and after their export may find, in the immediate
vicinity of this cell, conditions conducive to the generation
of conformational intermediates, oligomer formation and then
fibril deposition. However, IAPP is instructive for another reason.
Its fibrils are found throughout the islets though not beyond
its confines (de Koning et al., 1994a; Ma et al., 2000). If this
protein, or its initial conformational intermediates, can diffuse
beyond its cell of origin why does the amyloid end abruptly
at the endocrine:exocrine interface and not also involve the
immediately adjacent exocrine portions of the pancreas? What
are the factors that restrict its deposition to the islets? The
converse to this question is, what keeps some amyloidogenic
proteins from being deposited as amyloid at/near their site of
synthesis, but allows them to be deposited at other anatomic
sites.
There are many forms of amyloid that fall into the class
of “extracellular amyloid deposition remote from the site of
synthesis of their protein precursors.” In fact most clinically
relevant forms of systemic amyloidosis belong in this category
and include AA amyloid (a consequence of persistent acute
inflammation), AL amyloid (a consequence of myeloma or B-
cells dyscrasias), ATTR (transthyretin amyloid, many forms of
which are a consequence of single amino acid substitutions),
Aβ2M (a consequence of long term hemodialysis), and several
additional forms of amyloid such as those derived from
fibrinogen (Asl et al., 1997) or apoA-I (Amarzguioui et al.,
1998; Benson, 2001). This list is not complete. Among the many
examples that can be discussed only AA, ATTR, and Aβ2M
will be considered. Together they identify questions that need
to be addressed if we are to understand, sift, and apply the
information from studies of in vitro fibril formation to the in vivo
setting.
The precursor to AA amyloid, SAA, is synthesized primarily
in the liver and during an inflammatory reaction its plasma
concentration may increase 1000 fold (McAdam et al., 1978).
However, the deposition of SAA as AA amyloid occurs first in the
spleen specifically the perifollicular zone within this organ as seen
inmice andmink (Husby et al., 1975; Snow and Kisilevsky, 1985),
and extensive follicular splenic deposition in humans (Buck and
Koss, 1991; the “sago spleen” in Fontanus’ original description
of 1639). Why is this so? The follicle is the filtering zone within
the spleen and one may argue that high plasma concentrations of
SAA may lead to the formation of conformational intermediates
and oligomers which are cleared by the spleen. If it is true, as
shown in vitro, that conformational intermediates and oligomer
formation is a common pathway from amyloid precursors to
amyloid deposits then other amyloid precursors that exist in
plasma should also follow this anatomic deposition pattern. This
however is not the case. This follicular amyloid distribution
is peculiar to AA amyloid. TTR, the precursor to ATTR, is
also made primarily in the liver but its varying anatomic
distribution as amyloid appears to be related to particular
mutations. Wild-type TTR is seen mainly in the heart and in
older individuals (Benson, 2012), the peripheral nervous system
is the preference of one mutation (Benson and Uemichi, 1996),
in another mutation deposition is almost exclusively in the heart
(Buxbaum et al., 2010) and in yet another it is apparently in the
leptomeninges (Benson, 1996; Nakagawa et al., 2008). The spleen
is rarely, if ever, involved in ATTR regardless of the presence
or absence of mutations. Similarly, fibrinogen and apoA-I are
synthesized in the liver but are deposited in extra-hepatic sites. It
appears therefore that if protein concentration, conformational
instability, and oligomers play the role proposed in vitro it is
more likely that the unstable forms and early aggregates are
generated not close to the cell which synthesizes the precursor
or in plasma but more likely in the micro-locale where these
proteins are finally deposited.We know very little about potential
micro-environmental factors (ligands, temperature, pH, shear
forces, protein concentration, or removal of chaperones), how
they are generated, how they determine which organ is targeted
by the different amyloidogenic proteins, and in particular why
single amino acid substitutions in a specific amyloidogenic
protein (e.g., TTR, apoA-I, or β2M) changes the organs
involved.
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POTENTIAL FACTORS INFLUENCING
TISSUE TARGETING
The fact that single amino acid substitutions can change the
tissue site of amyloid deposition suggests that some of the
information determining this deposition resides in the structural
and functional features of the amyloidogenic protein itself. But
with what does the amyloidogenic protein interact and what is
the effect of this environment? Though possible, it is unlikely that
the ionic composition of interstitial fluid in tissue stroma varies
significantly in different organs, or from one locale to another
within the same organ. This suggests that attention should focus
on larger molecular entities with which the amyloidogenic
proteins may interact. Several possibilities come to
mind.
1. Protein:protein interactions in the extracellular matrix
are extremely varied and span a large range of affinities,
from the low affinity of chaperones proteins to the high
affinity of specific receptors. An example of the latter
is the high affinity binding of SAA, the AA precursor,
to laminin, a stromal protein. SAA has been shown to
compete with entactin (a normal laminin ligand necessary
for the building of basement membrane structures) for the
laminin:entactin binding site (Ancsin and Kisilevsky, 1997,
1999). The interaction with the hydrophobic surfaces of
fibrous proteins, constitutive components of the extracellular
matrix, is also extremely important although the interaction
is not specific for the amyloidogenic proteins. However,
the effect of the interaction of hydrophobic surfaces
and globular amyloidogenic proteins may be sufficiently
specific that once such contact is made the amyloidogenic
protein can unfold locally and its propensity to self-
aggregate enhanced (Husby et al., 1994; Relini et al., 2006,
2008).
2. Protein:proteoglycan binding, particularly HSPG and its
HS side chains. There is a substantial literature implicating
HS in amyloidogenesis in vivo (Kisilevsky et al., 2007).
Though HS has a common repeating disaccharide backbone
that is the same from tissue to tissue and cell to cell,
there is extensive variation in its pattern of sulfation and
epimerization to account for different specificities between
different tissues and for different specificities within the
same tissue. Furthermore, these HS structural variations
change with age and physiological states (Feyzi et al., 1998;
Parish, 2006) and may explain why amyloids are more
common later in life. Shear forces have been implicated
in the clustering of HS (Zeng et al., 2013) and both of
these factors have been shown to have an effect on protein
fibrillization. Heparan sulfate has also been shown to play
a role in dissociating SAA from HDL, its normal carrier
in plasma (Noborn et al., 2012), and such a separation of
SAA from HDL may alter SAA’s conformational stability.
Precisely how proteins bind/interact with HS, where their
complimentary binding faces exist and how the specificities
of protein binding are determined is a subject that cuts
across many areas of research (Kisilevsky and Ancsin,
2010). Nevertheless, this binding has been used successfully
as a therapeutic target in treating AA amyloidosis in
animals and humans (Kisilevsky et al., 1995; Dember et al.,
2007).
CELL AND TISSUE INJURY CAUSED BY
AMYLOID DEPOSITS
At least two pathological mechanisms are apparently involved
in amyloid causing cell and tissue injury. There may be
others to be discovered in the future. Historically, the first
mechanism is based on the gross and microscopic appearance
of amyloid as seen at the organ and tissue levels (Kisilevsky,
2007). Organs infiltrated with large quantities of amyloid,
regardless of type, become rigid and this rigidity may affect
their function (e.g., the heart). At a histological level amyloid
is deposited between blood vessels and parenchymal cells using
the stromal architecture of the extracellular matrix (Kisilevsky,
2007). This is believed to impair the transfer of nutrients to, and
of metabolic and functional products from, parenchymal cells
affecting their physiological function. Histological observations
also suggest that amyloid in situ surrounds parenchymal cells
constricting the space about these cells (Kisilevsky, 2007). Such
processes altering cell viability and function were suggested
decades before the fibrillar nature of amyloid was understood.
These older perspectives are no longer fashionable but there
is little experimental evidence that rules them out. Additional
proposals have arisen in the last 20 years based on cell/tissue
culture data. Attempts to determine if large amyloid deposits,
as seen histologically, had adverse properties vis a vis cell
viability and function in culture proved disappointing. However,
oligomeric units (small aggregates, not necessarily fibrillar) of
amyloidogenic proteins did influence cell viability (Haass and
Steiner, 2001; Glabe, 2006). It was therefore proposed that small
fibrils/oligomers, rather than large amyloid aggregates formed in
vivo were responsible for cell toxicity and altered cell function
seen in vivo. This conclusion needs to be tempered, and the
dismissal of the in vivo cell and tissue effects of large amyloid
deposits is premature because the anatomic relationship of large
aggregates to cells in culture is not analogous to amyloid seen
in the extracellular matrix between cells, and between cells and
capillaries in vivo. Nevertheless, there is ample evidence that
monomers and oligomers do have an effect on cell viability
in culture and in vivo. An interesting example of the former
is impaired cardiac function in AL amyloid and its positive
correlation with the plasma level of free amyloidogenic light
chains rather than the quantity of amyloid deposited in the heart
(Palladini et al., 2006). However, in these patients to fully express
their toxicity the soluble prefibrillar species requires the presence
of amyloid deposits in the tissues.
Additional studies have revealed that amyloidogenic
monomers can form beta barrels and they, as well as oligomers,
can insert themselves into cell membranes (plasma membranes
and intra-cellularly) altering cell permeability, or creating
membrane pores and impairing mitochondrial and endoplasmic
reticulum function with devastating consequences (Haass and
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Steiner, 2001; Glabe, 2006). Monomers, oligomers as well as
large amyloid deposits may be operative in vivo but only the first
two can be demonstrated in culture. Furthermore, in vivo their
effects may be additive or synergistic and their adverse effects
fully expressed when both fibrils and precursor are abundantly
present. Additionally, amyloid fibrils in the extracellular matrix
may enhance the mis-folding and aggregation of adjacent
corresponding precursor globular proteins (Bellotti and Chiti,
2008). To study such questions it may be possible to generate
scaffolds that mimic the extracellular matrix and use them as
tools to study the interplay between matrix, amyloid precursors,
and amyloid fibrils.
SUMMARY
A consideration of the general determinants that govern which
tissues are targeted by which amyloidogenic proteins is an aspect
that at present is not being, or cannot be, addressed/assessed
in vitro. The generation of critical protein concentrations and
the behavior of conformational intermediates and oligomers in
vitro do not necessarily indicate how and where these are formed
in vivo. They are not likely to be formed adjacent to the cells
synthesizing the protein nor in plasma as, being particulate, they
would likely be cleared by the reticulo-endothelial system and the
different amyloids would have very similar tissue distributions.
This suggests that conformational intermediates and oligomers
are generated close to the site of amyloid deposition, and are
subject to the same factors that determine the specific tissue
distribution of amyloids.
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